Ticker

MORRISTOWN, N.J., March 17, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it will present three preclinical abstracts, including an oral minisymposium and two posters, highlighting its…

Ally Bridge Group NY LLC acquired a new stake in Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 817,939 shares of the company's stock, valued at approximately $1,554,000. Whitehawk Therapeutics accounts for 0.9%

Avoro Capital Advisors LLC acquired a new position in shares of Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,849,402 shares of the company's stock, valued at approximately $5,414,000. Whitehawk Therapeutics comprises 0.1% of Avoro

Actively recruiting Phase 1 trials for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 and MUC16-targeted ADC HWK-016 HWK-206 on track for planned IND submission in mid-2026 and Phase 1 start in Q3 Cash, cash equivalents and short-term investments balance of $145.7M at YE2025, anticipated to fund operations into 2028 MORRISTOWN, N.J., March 12, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a…

Whitehawk Therapeutics (NASDAQ: WHWK - Get Free Report) and Vincerx Pharma (NASDAQ: VINC - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings. Analyst Recommendations This is a breakdown of